An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease
Overview
- Phase
- Phase 3
- Intervention
- S-1/Cisplatin
- Conditions
- Gastric Cancer
- Sponsor
- Taiho Oncology, Inc.
- Enrollment
- 1053
- Locations
- 33
- Primary Endpoint
- Median Survival
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or non-measurable disease, and center.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- •Has given written informed consent
- •Has histologically confirmed, unresectable, locally advanced (Stage IV) or metastatic gastric cancer, including adenocarcinoma of the gastro-esophageal junction
- •Has measurable or evaluable but non-measurable disease, defined as follows:
- •Measurable Disease - Patients with measurable disease as defined by RECIST criteria, i.e., the presence of at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter \>_ 20 mm using conventional techniques or \>_ 10 mm using spiral Computed Tomography (CT)scan. Locally recurrent disease (other than primary) is accepted if there is at least one measurable lesion (i.e. peritoneal mass, lymph node, etc.)
- •Evaluable but Non-measurable Disease - Patients with all lesions below the limits defined above for measureable disease (i.e., longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT) excluding those patients with only a primary lesion and/or with only non-evaluable cancer such as bone metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis of the skin or lung, previously irradiated lesions not in progression, or peritoneal carcinomatosis \< 10 mm in diameter with conventional imaging techniques.
- •No prior palliative chemotherapy is permitted. Adjuvant and /or neo-adjuvant chemotherapy is permitted if more than 12 months have elapsed between the end of adjuvant or neo-adjuvant therapy and first recurrence. This does not qualify as 1st line therapy.
- •Is able to take medications orally
- •Is \>_ 18 years of age
- •Is at least 3 weeks from prior major surgery
Exclusion Criteria
- •Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
- •Has had a treatment with any of the following within the specified timeframe prior to study drug administration:
- •Any prior palliative chemotherapy or any previous therapy for malignancy, including any chemotherapy, immunotherapy, biologic or hormonal therapy, within the past 5 years.
- •Adjuvant or neo-adjuvant therapy within the past 12 months
- •Concurrent treatment with any investigational anti-cancer agent
- •Prior cisplatin as neo-adjuvant and /or adjuvant chemotherapy with cumulative dose \> 300 mg/m
- •\> 25% of marrow-bearing bone radiated
- •Concurrent treatment with an investigational agent or within 30 days from randomization
- •Concurrent enrollment in another clinical study
- •Has a serious illness or medical condition(s) including, but not limited to the following:
Arms & Interventions
A
In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
Intervention: S-1/Cisplatin
B
In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
Intervention: 5-FU/cisplatin
Outcomes
Primary Outcomes
Median Survival
Time Frame: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.
Secondary Outcomes
- Duration of Response (DR)(Data cutoff was 07 March 2008 (12 months after last patient was randomized).)
- Overall Response Rate (ORR)(Data cutoff was 07 March 2008 (12 months after last patient randomized).)
- Progression-free Survival (PFS)(From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.)
- Time to Treatment Failure (TTF)(From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.)